Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves AbbVie’s Skyrizi to treat Crohn’s Disease in adults
The medicine is said to be the first and only specific interleukin-23 (IL-23) inhibitor approved for treating moderately to severely active CD in adults. The approval follows the
The medicine is said to be the first and only specific interleukin-23 (IL-23) inhibitor approved for treating moderately to severely active CD in adults. The approval follows the
With this FDA approval, IMCIVREE is indicated for chronic weight management in adult and pediatric patients aged six years and older with monogenic or syndromic obesity due to
This agreement will allow Quoin to offer healthcare professionals and patients in greater China, including Hong Kong, Macau and Taiwan, with access to its products following receipt regulatory
A pre-clinical stage biotech company, Trutino Biosciences is engaged in discovering and developing next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim has a two-pronged research
Olumiant is marked as the first and only systemic medicine for severe AA adult patients. It is an oral and once-daily JAK inhibitor which is available through specialty
The collaboration will use ImmunoGen’s linker-payload technology which is directed to new targets that are identified by OBT through its OGAP discovery platform. The two companies will jointly
Under the terms of the deal, Bavarian Nordic will be responsible for the supply of 500,000 additional doses of Jynneos vaccines this year. Previously in 2020, the company
Under the deal, Aurigene will receive $8m of upfront licensing payment for rights to the company’s pre-existing programme. The company will also be eligible for up to $60m
The antibody is indicated to treat R/R FL patients who have received at least two prior systemic therapies. Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that targets
The regulatory approval has been granted for the therapy to treat moderate-to-severe atopic dermatitis in children whose disease is not controlled with topical prescription therapies or when they